Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
business
business sponsored company news
articles containing video clips
colloids
dosage forms
drug delivery devices
gels
histopathology
infectious causes of cancer
male genital neoplasia
neoplastic and hyperplastic prostate disorders
physical chemistry
prostate cancer
rtt
american medical association
anaerobic digestion
biodegradable waste management
biodegradation
cancer screening
companies based in minneapolis
companies established in 1895
companies listed on the new york stock exchange
dialysis
features
free
funding
fundings & exits
gemspring capital
genomic medicine
genomic testing
health
health tech
health/life sciences
healthtech
illinois
investment banks
lucence diagnostics
med-tech
medical
medical and health professional associations in chicago
What
develops
20
×
technology
20
×
company
medical
augmenix
hydrogels
manufactures
organs
press
protect
radiotherapy
release
risk
sells
separate
absorbable
announced
proprietary
today
prostate
announces
hydrogel
spaceoar
cancer
annual
healthcare
new
private
radiation
american
conference
data
partners
present
treated
use
association
based
clinical
code
Language
unset
unknown
Current search:
technology
×
develops
×
@geekwire.com
6 months ago
Seattle-based health software company Valant sold to another private equity firm
@techcrunch.com
4 years ago
Lucence raises $20 million Series A for its non-invasive cancer screening technology
@tech.eu
4 years ago
British medtech company Quanta raises $48 million in Series C funding as it gears up for commercial launch
@venturebeat.com
6 years ago
Augmenix to Present at the 36th Annual J.P. Morgan Healthcare Conference
@venturebeat.com
6 years ago
Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018
@venturebeat.com
6 years ago
Augmenix Partners with Us TOO International to Stream Live Webcast and Q & A on Prostate Cancer Radiation Therapy
@venturebeat.com
6 years ago
Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy of SpaceOAR
@venturebeat.com
6 years ago
Augmenix to Unveil New Clinical Data on its Innovative Absorbable Hydrogel Technology at the 59th Annual Meeting of the American Society for Radiation Oncology
@venturebeat.com
6 years ago
NICE Announces Interventional Procedure Guidance Supporting Use of Hydrogel Spacer in Treatment of Prostate Cancer in the UK
@venturebeat.com
6 years ago
Augmenix, Inc. Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR® Hydrogel
@venturebeat.com
6 years ago
Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year
@venturebeat.com
6 years ago
Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR® Hydrogel in Israel
@venturebeat.com
6 years ago
Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in New Zealand
@venturebeat.com
7 years ago
SpaceOAR® System Receives Shonin Approval in Japan
@venturebeat.com
7 years ago
Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in Canada
@venturebeat.com
7 years ago
Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment
@venturebeat.com
7 years ago
Augmenix Announces Positive Three-Year Long-Term Data Highlighting Benefits of SpaceOAR® Hydrogel Spacer for Patients with Prostate Cancer
@venturebeat.com
7 years ago
Augmenix To Present at the 35th Annual J.P. Morgan Healthcare Conference
@venturebeat.com
7 years ago
Augmenix to Present at the Annual Piper Jaffray Healthcare Conference on Wednesday, November 30
@venturebeat.com
7 years ago
Augmenix Announces New Category 1 CPT® Code from the American Medical Association for Periprostatic Implantation of Biodegradable Material